Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 21 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-14.45 Insider Own1.45% Shs Outstand2.53M Perf Week66.43%
Market Cap5.89M Forward P/E- EPS next Y-1.76 Insider Trans92.96% Shs Float2.49M Perf Month44.72%
Income-27.78M PEG- EPS next Q-4.43 Inst Own9.52% Short Float1.80% Perf Quarter20.73%
Sales0.00M P/S- EPS this Y38.98% Inst Trans- Short Ratio0.06 Perf Half Y-52.51%
Book/sh0.02 P/B99.11 EPS next Y79.82% ROA-180.60% Short Interest0.04M Perf Year-74.72%
Cash/sh0.30 P/C7.66 EPS next 5Y- ROE-242.41% 52W Range1.09 - 10.24 Perf YTD-56.97%
Dividend Est.- P/FCF- EPS past 5Y92.12% ROI-51181.90% 52W High-77.25% Beta2.99
Dividend TTM- Quick Ratio0.87 Sales past 5Y-20.34% Gross Margin- 52W Low113.74% ATR (14)0.32
Dividend Ex-Date- Current Ratio0.87 EPS Y/Y TTM-37.03% Oper. Margin0.00% RSI (14)67.78 Volatility46.48% 21.24%
Employees17 Debt/Eq0.00 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price7.00
Option/ShortNo / No LT Debt/Eq0.00 EPS Q/Q-7.47% Payout- Rel Volume12.52 Prev Close1.89
Sales Surprise- EPS Surprise55.58% Sales Q/Q- EarningsMay 14 AMC Avg Volume797.15K Price2.33
SMA2040.90% SMA5044.14% SMA200-47.07% Trades Volume9,976,565 Change23.28%
Date Action Analyst Rating Change Price Target Change
Nov-19-20Initiated Maxim Group Buy $8
Jun-20-24 10:00AM
Jun-18-24 07:00AM
Jun-07-24 07:22AM
May-29-24 09:00AM
May-17-24 08:00AM
08:19AM Loading…
May-15-24 08:19AM
May-14-24 04:00PM
May-07-24 09:00AM
Apr-04-24 12:30PM
Mar-28-24 09:00AM
Mar-12-24 09:00AM
Mar-06-24 09:00AM
Mar-02-24 08:45AM
Feb-29-24 04:00PM
09:00AM Loading…
Feb-22-24 09:00AM
Feb-19-24 09:00AM
Feb-13-24 09:00AM
Feb-06-24 09:00AM
Jan-29-24 09:00AM
Jan-08-24 09:00AM
Jan-04-24 09:00AM
Jan-03-24 09:00AM
Dec-27-23 09:00AM
Dec-19-23 09:00AM
Dec-06-23 07:00AM
Dec-05-23 07:00AM
Nov-30-23 04:30PM
Nov-29-23 09:00AM
Nov-28-23 09:00AM
09:00AM Loading…
Nov-14-23 09:00AM
Nov-10-23 10:24AM
Nov-08-23 04:00PM
Nov-01-23 07:00AM
Oct-31-23 09:00AM
Oct-30-23 09:00AM
Oct-25-23 09:00AM
Oct-24-23 09:00AM
Oct-09-23 09:00AM
Oct-05-23 09:00AM
Oct-04-23 07:00AM
Oct-03-23 07:00AM
Sep-27-23 09:00AM
Sep-26-23 09:00AM
Sep-21-23 09:35AM
Sep-20-23 09:00AM
Sep-19-23 09:00AM
Sep-12-23 09:00AM
Sep-11-23 09:00AM
Aug-31-23 09:00AM
Aug-29-23 09:00AM
Aug-28-23 09:00AM
Aug-11-23 12:47PM
Aug-10-23 09:00AM
Aug-09-23 04:00PM
Jul-26-23 09:00AM
Jul-24-23 09:00AM
Jul-20-23 09:00AM
Jul-10-23 09:00AM
Jun-28-23 09:00AM
Jun-27-23 10:15AM
May-31-23 09:00AM
May-25-23 09:00AM
May-24-23 04:32PM
May-15-23 09:00AM
May-09-23 09:00AM
May-04-23 04:00PM
Apr-26-23 09:00AM
Apr-25-23 09:00AM
Apr-17-23 09:00AM
Apr-06-23 10:00AM
Apr-05-23 01:30PM
Mar-30-23 11:00AM
Mar-27-23 07:08AM
Mar-23-23 04:00PM
Mar-15-23 09:00AM
Mar-09-23 09:00AM
Mar-06-23 09:00AM
Feb-27-23 09:00AM
Feb-15-23 09:00AM
Feb-08-23 09:00AM
Feb-07-23 09:00AM
Jan-26-23 09:00AM
Jan-25-23 11:00AM
Jan-04-23 09:00AM
Dec-20-22 09:00AM
Dec-07-22 04:00PM
Nov-28-22 10:15AM
Nov-11-22 05:46AM
Nov-09-22 04:00PM
Oct-31-22 10:33AM
Oct-26-22 09:00AM
Oct-11-22 09:00AM
Oct-06-22 09:00AM
Sep-07-22 09:00AM
Sep-01-22 09:00AM
Aug-18-22 10:27AM
Aug-17-22 09:29AM
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus, as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DODD DAVID APresident, CEOFeb 22 '24Buy2.278,20918,66318,661Feb 22 04:41 PM
DODD DAVID APresident, CEOFeb 21 '24Buy2.155201,11810,452Feb 22 04:41 PM
Reynolds MarkCFOFeb 07 '24Buy2.772,0005,5407,213Feb 07 04:43 PM
McKee Kelly T. Jr.Chief Medical OfficerDec 22 '23Buy0.366,9442,50035,782Dec 26 03:51 PM
McKee Kelly T. Jr.Chief Medical OfficerSep 25 '23Buy0.529,6535,02028,838Sep 27 04:33 PM
DODD DAVID APresident, CEOAug 25 '23Buy0.5735,08720,000148,957Aug 28 04:05 PM
Reynolds MarkCFOAug 18 '23Buy0.5210,0005,17978,184Aug 21 08:39 AM